HealthQuill Breast cancer
Daiichi Sankyo and AstraZeneca’s treatment for breast cancer, Enhertu, has been approved as a monotherapy in the European Union, the companies announced.
Drugs Medical Pharma

EU green lights AstraZeneca, Daiichi’s treatment for breast cancer

HQ Team April 4, 2025: Daiichi Sankyo and AstraZeneca’s treatment for breast cancer, Enhertu, has been approved as a monotherapy in the European.

Read More
AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the Anglo-Swedish company.
Drugs Health Pharma

AstraZeneca says trial breast cancer drug improves survival rates

AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the.

Read More
Annual deaths caused by breast cancer globally will rise 68% to 1.1 million by 2050, according to a report from the International Agency for Research on Cancer, a specialised arm of the World Health Organization.
Drugs Health Pharma

Breast cancer death rates globally to rise 68% by 2050: WHO arm IARC warns

Annual deaths caused by breast cancer globally will rise 68% to 1.1 million by 2050, according to a report from the International Agency.

Read More
Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug regulator in the adult population. 
Drugs Health Pharma

AstraZeneca-Daiichi’s breast cancer drug gets broader US nod

Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.

Read More
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs Health Pharma

AstraZeneca’s medicine to treat a type of breast cancer gets US nod

AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.

Read More
Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of its breast cancer therapy, Keytruda.
Health Medical

Hormonal contraceptives and breast cancer risk in BRCA1 carriers

HQ Team January 17, 2025: A study has found a significant association between the use of hormonal contraceptives and an increased risk of.

Read More
Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid tumours, for $2.5 billion in cash.
Drugs Health Medical

Eli Lilly to buy Scorpion Therapeutics’ cancer drug for $2.5 billion

Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid.

Read More
AstraZeneca, Daiichi’s breast cancer drug trial results show improvement in progression-free survival
Climate Health Medical

Plastic pollution has increased breast cancer rates globally

HQ Team December 30, 2024: Researchers have identified a strong link between plastics and the rising incidence of breast cancer. Breast cancer has.

Read More
Uncategorized

Elevated β-hCG linked to BRCA1 mutations in breast cancer

Bharti Jayshankar December 16, 2024: Researchers at the Rajiv Gandhi Biotechnology Centre, Kerala, delving into the molecular mechanisms of tumorigenesis by BRCA1 gene,.

Read More
Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of its breast cancer therapy, Keytruda.
Drugs Pharma

AstraZeneca, Merck announce promising results for breast cancer in trial 3

Bharti Jayshankar December 13, 2024: AstraZeneca and Merck have announced long-term results from the OlympiA Phase 3 trial, showing that Lynparza (olaparib) significantly.

Read More